Related Experiment Video
Updated: Aug 9, 2026

Genome-wide Analysis using ChIP to Identify Isoform-specific Gene Targets
Published on: July 7, 2010
Epigenetic inactivation of Betaig-h3 gene in human cancer cells
Genze Shao1, Jessica Berenguer, Alain C Borczuk
1Center for Radiological Research and Department of Pathology, Columbia University, New York, New York 10032, USA.
Abstract:
Gene silencing by CpG island methylation in the promoter region is one of the mechanisms by which tumor suppressor genes are inactivated in human cancers. It has been shown previously that Betaig-h3 gene, which encodes an extracellular matrix protein involved in cell adhesion and tumorigenesis, is down-regulated or silenced in a variety of human cancer cell lines. To unravel the underlying molecular mechanism(s) for this phenomenon, DNA methylation patterns of Betaig-h3 CpG island were examined in normal, immortalized, and cancer cell lines derived from lung, prostate, mammary, and kidney. A good correlation was observed between promoter hypermethylation and lost expression of Betaig-h3 gene, which was supported by the data that demethylation of promoter by 5-aza-2'-deoxycytidine reactivated Betaig-h3 and restored its expression in Betaig-h3-silenced tumor cell lines. This result was further substantiated by a luciferase reporter assay, showing the restoration of promoter activities and increased response to transforming growth factor-beta treatment in Betaig-h3-negative 293T cells when transfected with unmethylated Betaig-h3 promoter. In contrast, activity of Betaig-h3 promoter was completely inactivated by in vitro methylation. Furthermore, CpG methylation of Betaig-h3 promoter was also shown in primary lung tumors that expressed decreased level of Betaig-h3 protein. These results suggest that promoter methylation plays a critical role in promoter silencing of the Betaig-h3 gene in human tumor cells.
Insights
CpG island methylation silences the Betaig-h3 gene in human cancers. Demethylation reactivates Betaig-h3 expression, suggesting promoter methylation is critical for tumor suppressor gene inactivation.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Gene silencing via promoter CpG island methylation is a key mechanism for tumor suppressor gene inactivation in human cancers.
- The Betaig-h3 gene, encoding an extracellular matrix protein, is frequently downregulated or silenced in various cancer cell lines.
- Understanding the molecular mechanisms behind Betaig-h3 silencing is crucial for cancer research.
Purpose of the Study:
- To investigate the role of DNA methylation in the promoter region of the Betaig-h3 gene in human cancers.
- To determine the correlation between Betaig-h3 promoter methylation and gene expression levels.
- To explore the potential of demethylation agents in restoring Betaig-h3 expression.
Main Methods:
- Analysis of DNA methylation patterns in the Betaig-h3 CpG island across normal, immortalized, and cancer cell lines (lung, prostate, mammary, kidney).
- Treatment of silenced tumor cell lines with 5-aza-2'-deoxycytidine to induce demethylation and assess gene reactivation.
- Luciferase reporter assays to evaluate the functional impact of Betaig-h3 promoter methylation and demethylation on gene activity.
- Examination of Betaig-h3 promoter methylation and protein levels in primary lung tumors.
Main Results:
- A strong correlation was observed between hypermethylation of the Betaig-h3 promoter and the loss of gene expression.
- Demethylation using 5-aza-2'-deoxycytidine successfully reactivated Betaig-h3 expression in silenced cancer cell lines.
- Luciferase assays confirmed that unmethylated Betaig-h3 promoter restored activity, while in vitro methylation inactivated it.
- CpG methylation of the Betaig-h3 promoter was detected in primary lung tumors with reduced Betaig-h3 protein levels.
Conclusions:
- Promoter methylation plays a critical role in the silencing of the Betaig-h3 gene in human tumor cells.
- Betaig-h3 gene silencing through promoter hypermethylation is a significant mechanism in cancer development.
- Targeting epigenetic modifications like DNA methylation could offer therapeutic strategies for cancers involving Betaig-h3 silencing.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Histone Variants at the Centromere
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Position-effect Variegation
